Bluebird Bio | BLUE - Gross Profit On Sales


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Bluebird Bio

Bluebird Bio reported $-995000 in Gross Profit on Sales for its fiscal quarter ending in March of 2023.


Gross Profit On Sales Change
Agios Pharmaceuticals AGIO:US USD 5.06M 1.16M
Alnylam Pharmaceuticals ALNY:US USD 264.42M 19.35M
Amgen AMGN:US USD 4.42B 669M
Biogen BIIB:US USD 1.8B 172.9M
BioMarin Pharmaceutical BMRN:US USD 469.87M 59.62M
Bluebird Bio BLUE:US USD -995000 1.04M
Gilead Sciences GILD:US USD 4.95B 1.04B
Immunogen IMGN:US 49.24M 8.25M
Incyte Corp INCY:US USD 757.25M 115.69M
Intercept Pharmaceuticals ICPT:US USD 67.74M 9.46M
Ionis Pharmaceuticals IONS:US USD 129.18M 19.02M
Mirati Therapeutics MRTX:US 6.35M 6.02M
Moderna Inc MRNA:US USD 1.07B 2.1B
Nektar Therapeutics NKTR:US USD 14.53M 1.26M
Novartis NOVN:VX USD 9.38B 215M
Pfizer PFE:US USD 13.26B 1.21B
PTC Therapeutics PTCT:US USD 206.24M 49.72M
Regeneron Pharmaceuticals REGN:US USD 2.7B 169.2M
Sarepta Therapeutics SRPT:US USD 218.48M 9.14M
Seattle Genetics SGEN:US USD 407.94M 12M
Ultragenyx Pharmaceutical RARE:US USD 88.24M 9.79M
Vertex Pharmaceuticals VRTX:US USD 2.11B 88.5M